

09:45 – 10:00	Tea/coffee, registration
10:00 – 10:05	Welcome, day's overview - Bina Mukhtyar
10:05 – 10:20	EPEN website documents review – Peter Rose, Peterborough
10:20 – 10:35	Acquired Brain injury (ABI) audit - Pooja Pankhania (med student) Apostolos Papandreou – <i>followed by 5 min Q&A</i>
10:40 – 11:00	Acquired brain injury pathway - Suzanna Watson, Apostolos Papandreou- <i>followed by 5 min Q&A</i>
11:05 – 11:20	Tea/coffee break
11:20 – 12:10	GUEST LECTURE – Surgically amenable epilepsies in children. Suresh Pujar, Consultant Paed Neurologist, CESS service, GOSH (including 10-15min Q&A/discussion around CESS related issues)
12:10 – 12:30	Tone Management Pathway- Apostolos Papandreou, Jo Coghill, CUH - <i>followed by 5 min Q&A</i>
12:35 – 12:45	OPEN UK/NHSE update- Richard Brown, CUH
12:45 - 13.45	Lunch and time to catch up with our sponsors
13:45 – 14:00	Epilepsy audit - Renagashri (Med Student), Pooja Harijan - <i>followed by 5 min Q&A</i>
14:05 – 14:20	Audit of topiramate use and pregnancy prevention program - Liam (med student), Katie Burton, CUH (<i>followed by 5 min Q&A</i>)
14:25 – 14:45	Case 1 -Sadia Bashir, Sreeni Tekki-Rao, Luton (<i>followed by 5 min Q&A</i>)
14:50 – 15:10	Case 2 – Vivek Kalra, NNUH - <i>followed by 5 min Q&A</i>
15:15 – 15:25	Tea/coffee break
15:25 – 15:45	Case 3 – Sreeni Tekki-Rao, Luton (<i>followed by 5 min Q&A</i>)
15:50 - 16:10	Case 4 – Arun Saraswatula, WSH (<i>followed by 5 min Q&A</i>)
16:15-16.35	Case 5- Angeliki Menounou, Colchester (<i>followed by 5 min Q&A</i>)
16.40-17.00	AoB/ Feedback and close

The following pharmaceutical companies have kindly agreed to sponsor this educational event via payment towards the fees/sponsorship of the speakers and venue. Sponsors have had no involvement in the organisation or content of the meeting.





Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing medicines for people with serious diseases – often with limited or no therapeutic options.



Biocodex develops and markets drugs for patients with severe orphan diseases. In the early 1990's, our R&D in Compiègne found and developed an anti-epileptic drug indicated for a newly discovered rare and severe epileptic disorder: Dravet Syndrome. Since then, we have been committed to raising awareness on rare epilepsies alongside healthcare professionals, patients and caregivers. Our aim is to provide effective, innovative products and services that help lighten the disease burden for patients and their families.

In 2021, Biocodex was granted the exclusive rights to distribute another product in most European countries on behalf of Orphelia Pharma. This anti-epileptic drug is indicated for the treatment of a severe and rare epileptic disorder in children: West Syndrome.

Working alongside all the relevant stakeholders, Biocodex is committed to improving knowledge for an earlier diagnosis and optimal management of rare epilepsies.



UCB Pharma is a global biopharmaceutical company with over 30 years of dedication to improving care for people with epilepsy. They have developed several key epilepsy treatments—supporting individuals with common, complex, and rare epilepsies such as Dravet and Lennox-Gastaut syndromes—and continue to drive research in areas like rapid seizure management and developmental and epileptic encephalopathies.

They also work closely with patient organisations and healthcare partners to enhance services, raise awareness, and support families living with epilepsy.



Proveca Ltd is a UK based pharmaceutical company specialising in the development and licensing of off-patent medicines for children throughout Europe.

Marketing approval (product licence) is gained via a Paediatric Use Marketing Authorisation (PUMA), a regulatory route developed specifically for licensing off-patent medicines for children in Europe. Proveca's first PUMA (Sialanar) was granted in September 2016.